|
Evoke Pharma Inc (NASDAQ: EVOK) |
|
Evoke Pharma Inc
EVOK's Fundamental analysis
Select the Comparisons :
|
|
Select the Ratio:
|
|
|
Looking into Evoke Pharma Inc growth rates, revenue grew
by 97.4 % in IV. Quarter 2024 from the same quarter a year ago.
Ranking at No. 400
Major Pharmaceutical Preparations industry recorded
growth of revenues by 11.85 %
Evoke Pharma Inc net loss decreased from $-2 millions, to $-1 millions in IV. Quarter 2024,
• More on EVOK's Growth
|
|
Evoke Pharma Inc realized a net loss in trailing twelve months.
Company is currently trading with Price to Cash flow multiple of 0.55 in trailing twelve-month period. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Company's Price to Sales ratio is at 0.48.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.27.
• More on EVOK's Valuation
|
|
|
|
|
Evoke Pharma Inc realized net loss in trailing twelve months.
Company is currently trading with Price to Cash flow multiple of 0.55 in trailing twelve-month period. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Company's Price to Sales ratio is at 0.48.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.27.
Evoke Pharma Inc Price to Book Ratio is at 0.7 lower than Industry Avg. of 79.76. and higher than S&P 500 Avg. of 0.01
• More on EVOK's Valuation
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2025 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com